CoChat
Sign Up
Cited by 173Schizophrenia research and treatmentAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesNeurotransmitter Receptor Influence on Behavior

Anxiety in Patients with Schizophrenia: Epidemiology and Management

Temmingh, Henk, Stein, Dan J.·2015·CNS Drugs
DOI 10.1007/s40263-015-0282-7
Open this paper in CoChat — free account

Abstract

Anxiety symptoms can occur in up to 65 % of patients with schizophrenia, and may reach the threshold for diagnosis of various comorbid anxiety disorders, including obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD). We review the clinical presentation, diagnosis, neurobiology, and management of anxiety in patients with schizophrenia, with a particular focus on pharmacotherapy. The prevalence of any anxiety disorder (at syndrome level) in schizophrenia is estimated to be up to 38 %, with social anxiety disorder (SAD) being the most prevalent. Severity of positive symptoms may correlate with severity of anxiety symptoms, but anxiety can occur independently of psychotic symptoms. While anxiety may be associated with greater levels of insight, it is also associated with increased depression, suicidality, medical service utilization, and cognitive impairment. Patients with anxiety symptoms are more likely to have other internalizing symptoms as opposed to externalizing symptoms. Diagnosis of anxiety in schizophrenia may be challenging, with positive symptoms obscuring anxiety, lower levels of emotional expressivity and communication impeding diagnosis, and conflation with akathisia. Higher diagnostic yield may be achieved by assessment following the resolution of the acute phase of psychosis as well as by the use of screening questions and disorder-specific self-report instruments. In schizophrenia patients with anxiety, there is evidence of underactive fear circuitry during anxiety-provoking stimuli but increased autonomic responsivity and increased responsiveness to neutral stimuli. Recent findings implicate the serotonin transporter (SERT) genes, brain-derived neurotropic factor (BDNF) genes, and the serotonin 1a (5HT1a) receptor, but are preliminary and in need of replication. There are few randomized controlled trials (RCTs) of psychotherapy for anxiety symptoms or disorders in schizophrenia. For pharmacotherapy, data from a few randomized and open trials have shown that aripiprazole and risperidone may be efficacious for obsessive-compulsive and social anxiety symptoms, and quetiapine and olanzapine for generalized anxiety. Older agents such as trifluoperazine may also reduce comorbid anxiety symptoms. Alternative options include selective serotonin re-uptake inhibitor (SSRI) augmentation of antipsychotics, although evidence is based on a few randomized trials, small open trials, and case series, and caution is needed with regards to cytochrome P450 interactions and QTc interval prolongation. Buspirone and pregabalin augmentation may also be considered. Diagnosis and treatment of anxiety symptoms and disorders in schizophrenia is an important and often neglected aspect of the management of schizophrenia.

Integrity signals

Registry

Crossref · 10.1007/s40263-015-0282-7

Cites

153 of 153 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Depression and anxiety are strongly associated with positive symptoms, negative symptoms, psychotic relapses and impaired social function, and are among the best symptom predictors of quality of life outcomes in people with SSDs.

    “Depression and anxiety are strongly associated with positive symptoms,2,3,5–7,9 negative symptoms,2,8 psychotic relapses3,9 and impaired social function,3,5,9 and are among the best symptom predictors of quality of life outcomes in people with SSDs.2–9”

    From Dispositional Mindfulness and Psychotic Symptoms in Schizophrenia Spectrum Disorders: The Mediating Roles of Rumination and Negative Emotion (2022) · cites this paper as [9]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Temmingh, H., & Stein, D. J.
Affiliations
University of Cape Town (ZA)
Corresponding author
Temmingh, Henk
ORCID
Venue
CNS Drugs
Publisher
Springer Science and Business Media LLC
Published
2015-10
Volume
29
Issue
10
Pages
819-832
ISSN
  • 1172-7047 (ISSN-L)
  • 1179-1934
DOI
10.1007/s40263-015-0282-7
OpenAlex
W1790964085
Cited by
173
References
153
Citations by year
2026: 15 · 2025: 10 · 2024: 28 · 2023: 18 · 2022: 26 · 2021: 22 · 2020: 19 · 2019: 15 · 2018: 12 · 2017: 6 · 2016: 2
FWCI
0.92
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • CNS Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
schizophrenia, anxiety comorbidity, obsessive-compulsive disorder, post-traumatic stress disorder, social anxiety disorder, generalized anxiety disorder, akathisia, anxiety screening, neurobiology of anxiety, serotonin transporter gene, brain-derived neurotrophic factor, 5-HT1A receptor, aripiprazole, risperidone, quetiapine, olanzapine, trifluoperazine, SSRI augmentation, buspirone, pregabalin, antipsychotic pharmacotherapy
MeSH terms
Anxiety Disorders, Humans, Schizophrenia, Antipsychotic Agents, Anti-Anxiety Agents, Disease Management

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review